Sign in Subscribe
Universities and colleges

New Findings in Apoptosis: PRIMA-1 Shows Potential as Novel Chemotherapeutic Treatment

Strategic Insights

— 1 min read

Scientists from the University of Missouri's Dalton Cardiovascular Research Center have published a pilot study in the journal Endocrine-related Cancer, revealing promising results for the treatment of progestin-accelerated human breast cancer. The study, led by I. Benakanakere and colleagues, explores the effectiveness of PRIMA-1, a small-molecule compound that reactivates mutant p53, restoring its normal tumor suppressor function.

Key Takeaways:

  • PRIMA-1 caused regression of approximately 40% of progestin-accelerated DMBA-induced mammary tumors in Sprague-Dawley rats.
  • The compound did not induce regression of native non-progestin-accelerated DMBA-induced tumors.
  • PRIMA-1 suppressed the emergence of any new progestin-accelerated tumors in the model.
  • Tumor regression correlated with conversion of mutant to wild-type p53 conformation, reduced expression of vascular endothelial growth factor and estrogen receptor, lack of blood vessel perfusion, increased expression of p21, and massively increased expression of anti-angiogenic protein, secreted protein acidic and rich in cysteine.
  • The pre-clinical results suggest that PRIMA-1 has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast cancer.

Statistics:

  • Approximately 40% of progestin-accelerated DMBA-induced mammary tumors regressed after PRIMA-1 treatment.
  • 6 out of 8 progestin-accelerated DMBA-induced tumors expressed mutant p53 protein.
  • PRIMA-1 treatment reduced expression of vascular endothelial growth factor by [insert percentage].
  • Estrogen receptor expression was reduced by [insert percentage] after PRIMA-1 treatment.

Sources:

- Benakanakere, I., et al. (2009) Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Endocrine-related Cancer, 16(1), 85-98.

- University of Missouri, Dalton Cardiovascular Research Center.

- Cancer Weekly editors.

- NewsRx.com.

Read more